Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AGEN Agenus > Key Indicators
AGEN Agenus
2.700
+0.070+2.66%
Post Mkt Price
2.730
+0.030+1.11%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Receivable Turnover(T)
-77.78% 5.8765 312.88% 31.3346 409.03% 179.1772 2,087.51% 221.0579
Fixed Assets Turnover(T)
-83.61% 0.8159 159.42% 3.4024 126.54% 3.7189 108.18% 3.907
Total Asset Rate(T)
-78.28% 0.2075 172.25% 0.9872 124.36% 0.9165 82.26% 0.869
ROIC
-- -210.433% -- -- -- -- -- --
ROE
-- -2090.884% -- -- -- -- -- --
ROA
-4,513.40% -51.796% 104.66% 5.573% 93.94% -5.556% 92.76% -7.094%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -- 13.05% -75.443%
Profitability Ratios TTM
Gross Margin
-341.05% -112.076% 133.32% 41.236% 154.42% 39.565% 159.64% 38.418%
Operating Margin
-994.26% -198.775% 107.14% 15.861% 109.43% 14.085% 109.57% 12.591%
Net Margin
-20,419.41% -249.665% 101.71% 5.646% 97.30% -6.062% 96.03% -8.164%
EBITDA Margin
-825.84% -1.7391% 110.81% 0.2456% 110.51% 0.1511% 111.39% 0.1481%
R & D Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
257.23% 86.700% -74.19% 25.380% -66.75% 25.480% -61.54% 25.830%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- -- -- 1890.281% -- 301.718% -- 159.501%
Total Assets to Common Equity
-- -- -- 13354.040% -- 2807.641% -- 1352.956%
Debt to Asset Ratio
-- -- -- 2347.395% -- 409.168% -- 169.242%
Current Ratio
-29.28% 1.4528 228.76% 1.809 81.70% 1.7814 141.46% 2.1153
Quick Ratio
-30.48% 1.3119 262.60% 1.6111 84.31% 1.6189 152.66% 1.9653
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- -- 269.29% 100.316%
Revenue CAGR(5Y)
-- -- -- -- -- -- 133.13% 67.279%
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.
CEO: Dr. Garo H. Armen, Pd.D
Market: NASDAQ
Listing Date: 02/04/2000
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist